Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, et al. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. bioRxiv. 2023.

Panarelli NC, Hornick JL, Yantiss RK. What Is the Value of Counting Mast Cells in Gastrointestinal Mucosal Biopsies? Mod Pathol. 2023;36(2):100005.

Quintanilha JC, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, et al. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. JAMA Netw Open. 2023;6(1):e2252244.

Hwang JK, Bakotic WL, Gold JA, Magro CM, Lipner SR. Isolation of Terbinafine-Resistant Trichophyton rubrum from Onychomycosis Patients Who Failed Treatment at an Academic Center in New York, United States. J Fungi (Basel). 2023;9(7).

Boyraz B, Gogakos T, Raskin KA, Nielsen GP. Metastatic Uterine Leiomyosarcoma With Rhabdomyosarcomatous Heterologous Differentiation. Int J Gynecol Pathol. 2023;42(2):151-154.

Bhattacharya U, Kamran M, Manai M, Cristofanilli M, Ince TA. Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers (Basel). 2023;15(2).

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.

Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Lancet Haematol. 2023;10(8):e624-e632.

Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis GB, Mandell M, et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. NPJ Precis Oncol. 2023;7(1):9.

Mavragani CP, Kirou KA, Seshan SV, Crow MK. Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford). 2023;62(7):2534-2538.